Astellas Pharma Inc. (OTCMKTS:ALPMY) Short Interest Update

Astellas Pharma Inc. (OTCMKTS:ALPMY) saw a significant increase in short interest in November. As of November 15th, there was short interest totalling 100,500 shares, an increase of 1,004.4% from the October 31st total of 9,100 shares. Based on an average trading volume of 320,400 shares, the short-interest ratio is currently 0.3 days.

Astellas Pharma Trading Up 1.2 %

OTCMKTS ALPMY traded up $0.12 during trading hours on Friday, hitting $10.29. 181,212 shares of the company were exchanged, compared to its average volume of 199,832. The stock has a market cap of $18.62 billion, a PE ratio of 17.15 and a beta of 0.36. Astellas Pharma has a 52 week low of $9.15 and a 52 week high of $13.14. The stock has a 50-day moving average price of $11.30 and a 200 day moving average price of $10.97. The company has a quick ratio of 0.72, a current ratio of 0.90 and a debt-to-equity ratio of 0.26.

Astellas Pharma (OTCMKTS:ALPMY) last released its quarterly earnings results on Wednesday, October 30th. The company reported $0.13 earnings per share for the quarter. The company had revenue of $3.11 billion for the quarter. Astellas Pharma had a return on equity of 10.33% and a net margin of 3.26%. Analysts forecast that Astellas Pharma will post 0.61 earnings per share for the current fiscal year.

Astellas Pharma Company Profile

Astellas Pharma Inc manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer.